Sagimet Biosciences (SGMT) Cash & Equivalents (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Cash & Equivalents of $36.6 million for Q1 2026, down 43.41% year-over-year from $64.7 million in Q1 2025, and up 4.58% quarter-over-quarter from $35.0 million in Q4 2025.
Sagimet Biosciences (SGMT) Cash & Equivalents (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $36.6 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 43.41% year-over-year to $36.6 million; the TTM figure through Mar 2026 stood at $36.6 million (down 43.41% YoY), while the FY2025 annual figure was $35.0 million, down 53.82% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $36.6 million, up from $35.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $176.8 million in Q1 2024, with the low at $158000.0 in Q4 2022.
- The 5-year median for Cash & Equivalents is $64.7 million (2025), against an average of $64.0 million.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 47456.33% in 2023, then plunged 63.39% in 2025.
- Sagimet Biosciences' Cash & Equivalents stood at $158000.0 in 2022, then surged by 47456.33% to $75.1 million in 2023, then climbed by 0.93% to $75.8 million in 2024, then tumbled by 53.82% to $35.0 million in 2025, then gained by 4.58% to $36.6 million in 2026.
- Business Quant data shows SGMT's Cash & Equivalents at $36.6 million in Q1 2026, $35.0 million in Q4 2025, and $32.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 165.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.90 Mn |
| Mar 31, 2026 | 36.63 Mn |
| Dec 31, 2025 | 35.02 Mn |
| Sep 30, 2025 | 32.50 Mn |
| Jun 30, 2025 | 42.33 Mn |
| Mar 31, 2025 | 64.72 Mn |
| Dec 31, 2024 | 75.84 Mn |
| Sep 30, 2024 | 77.01 Mn |
| Jun 30, 2024 | 95.96 Mn |
| Mar 31, 2024 | 176.78 Mn |
| Dec 31, 2023 | 75.14 Mn |
| Sep 30, 2023 | 101.84 Mn |
| Jun 30, 2023 | 18.51 Mn |
| Dec 31, 2022 | 158,000.00 |